Brown Maria S, Akopiants Konstantin, Resceck Diane M, McArthur Hamish A I, McCormick Ellen, Reynolds Kevin A
Bioprocess R&D, Pfizer Global Research and Development, Groton Laboratories, Pfizer Inc., Eastern Point Road, Groton, Connecticut 06340, USA.
J Am Chem Soc. 2003 Aug 27;125(34):10166-7. doi: 10.1021/ja034540i.
Thiolactomycin (TLM), a natural product produced by both Nocardia and Streptomyces spp., is a potent and highly selective inhibitor of the type II dissociated fatty acid synthases of plants and bacteria. The unique mode of action of TLM and its low toxicity make it an attractive compound for development of new antimicrobial agents. In this study, incorporation studies with 13C-labeled precursors demonstrate that TLM is derived from one acetate-derived starter unit and three methylmalonate-derived extender units. The unusual thiolactone represented by TLM represents a novel class of polyketide-derived antibiotics in which an unusual cyclization process, which terminates the biosynthetic pathway, involves incorporation of a sulfur atom from l-cysteine. Manipulation of this pathway through techniques such a combinatorial biosynthesis and mutasynthesis may provide a new route for economically viable production of useful TLM analogues.
硫内酯霉素(TLM)是一种由诺卡氏菌属和链霉菌属产生的天然产物,是植物和细菌II型解离脂肪酸合酶的强效且高度选择性抑制剂。TLM独特的作用方式及其低毒性使其成为开发新型抗菌剂的有吸引力的化合物。在本研究中,用13C标记前体的掺入研究表明,TLM源自一个乙酸盐衍生的起始单元和三个丙二酸单酰基衍生的延伸单元。TLM所代表的不寻常硫内酯代表了一类新型的聚酮化合物衍生抗生素,其中终止生物合成途径的不寻常环化过程涉及来自L-半胱氨酸的硫原子的掺入。通过组合生物合成和突变合成等技术对该途径进行操作,可能为经济可行地生产有用的TLM类似物提供一条新途径。